Equities

Revelation Biosciences Inc

REVB:NAQ

Revelation Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.8444
  • Today's Change-0.016 / -1.86%
  • Shares traded1.07m
  • 1 Year change-96.18%
  • Beta0.1922
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Revelation Biosciences Inc have a median target of 16.95, with a high estimate of 25.00 and a low estimate of 8.90. The median estimate represents a 1,907.34% increase from the last price of 0.8444.
High2,860.7%25.00
Med1,907.3%16.95
Low954.0%8.90

Earnings history & estimates in USD

On Aug 09, 2024, Revelation Biosciences Inc reported 2nd quarter 2024 losses of -5.13 per share.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate-18.04%
Revelation Biosciences Inc reported annual 2023 losses of -0.530 per share on Mar 22, 2024.
Average growth rate+75.43%
More ▼

Revenue history & estimates in USD

Revelation Biosciences Inc did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Revelation Biosciences Inc did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.